Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard University, and the Massachusetts Institute of Technology (MIT), and went on to lead the development of Xolair, the world’s first anti-IgE drug—marking a groundbreaking milestone in the treatment of allergies and asthma.
After achieving remarkable success and reaching retirement, Dr. Chang embraced a new mission: to create world-class innovative drugs in Taiwan. He subsequently founded Immunwork and T-E Meds, continuing to dedicate himself to innovative drug development and advancing Taiwan’s biotechnology industry onto the global stage.
Chairman Interview Video:
Related News Coverage: